Drugs / CAStem
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04331613 | Jan → Dec 2020 | COVID-19, acute lung injury, acute respiratory distress syndrome, viral pneumonia | Chinese Academy of Sciences | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAStem | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04331613 ↗ |
| Modality | Cell therapy | “CAStem is an injectable product composed of immunity- and matrix-regulatory cells (IMRCs)” NCT04331613 ↗ |
| Route | Intravenous | “CAStem will be administered intravenously.” NCT04331613 ↗ |